In human randomized, double-blind clinical studies, DPP-4 inhibitors did not appear to reduce the risk of major adverse cardiovascular events among patients with type 2 diabetes without and with established cardiovascular disease [12–14]. Here, DPP4 is linked to cardiovascular disorder.